In a crowded AI-driven drug development sector, BenevolentAI stands out with its broad pipeline of drug candidates, deep pockets, and a growing partnership with AstraZeneca. Ivan Griffin, company co-founder and chief operating officer spoke with In Vivo about the formula behind the company’s successes.
While over 270 companies are doing artificial intelligence-driven drug development, many potential partners and investors are holding out for the first fruits of AI-based approaches. However, BenevolentAI Limited is being championed not only by investors, but by large pharma companies that have benefited from their work.
“There’s something happening in our sector,” said Ivan Griffin, co-founder and chief operating officer of the London, UK-headquartered biotech. “Investment...
Ovid Therapeutics' president and COO Meg Alexander is leading the company’s strategic pivot toward innovative neurological treatments, potentially creating a new class of medicines for rare neurological disorders.
Thijs Spoor's bet on lead-212 is paying off as Perspective Therapeutics advances three clinical programs with promising early efficacy signals and a comprehensive manufacturing strategy.
Namrata Saroj, chief business officer of Ocular Therapeutix, is highly respected in the retina community for her contributions to drug development. She talked to In Vivo about her journey in ophthalmology, leadership philosophy and the importance of authenticity in a close-knit specialty.
